Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A small registrational trial of FIRDAPSE® (amifampridine) Tablets for the treatment of Lambert-Eaton myasthenic syndrome

Next Previous
Trial Profile

A small registrational trial of FIRDAPSE® (amifampridine) Tablets for the treatment of Lambert-Eaton myasthenic syndrome

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 18 Dec 2023 According to a Catalyst Pharmaceuticals media release, DyDo Pharma, reported that it has submitted a New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency seeking marketing approval for FIRDAPSE Tablets 10 mg , for the treatment of Lambert Eaton myasthenic syndrome ("LEMS") in Japan, based on preliminary favorable analysis results of interim data after six months into the safety phase of the registration study.
  • 15 Mar 2023 According to a Catalyst Pharmaceuticals media release, the company anticipate completion of study in late 2023, and if the study is successful, the company anticipates the filing of an application to market the product in Japan in the second quarter of 2024.
  • 06 Dec 2021 Status changed from planning to recruiting, according to a Catalyst Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top